Tin tức & Cập nhật
Xem bài viết Dược
Xem
Chỉ hiển thị Multimedia

Post-treatment HBsAg loss greater with TDF vs entecavir
12 Jun 2023
In patients with chronic hepatitis B (CHB) without cirrhosis, the rates of hepatitis B surface antigen (HBsAg) loss appear to be higher after discontinuation of tenofovir disoproxil fumarate (TDF) than of entecavir, and this is particularly true for patients who have not experienced relapse after treatment discontinuation, according to a study.
12 Jun 2023

Progression-free on immunotherapy for NSCLC? Stopping treatment at 2 years may be OK
12 Jun 2023
bởiJairia Dela Cruz
For patients with advanced nonsmall cell lung cancer (NSCLC) who remain progression-free on immune checkpoint inhibitor (ICI)-based therapy at 2 years, continuing treatment does not appear to confer any survival advantage as opposed to stopping, according to a retrospective study presented at ASCO 2023.
12 Jun 2023






